MorphoSys AG
Lena-Christ-Strasse 48
Martinsried
Munich
82152
Germany
Tel: 49-0-89-899-27-0
Fax: 49-0-89-899-27-222
Website: http://www.morphosys.com/
Email: info@morphosys.com
574 articles about MorphoSys AG
-
MorphoSys AG Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
3/13/2024
MorphoSys AG (FSE: MOR; NASDAQ: MOR) reports results for the fourth quarter and the full year 2023.
-
Invitation to MorphoSys' Full Year Results 2023 Conference Call on March 14, 2024
3/7/2024
MorphoSys' Management team will host a conference call and webcast on March 14, 2024, at 01:00 pm CET to present the results for the financial year 2023 and provide an outlook for 2024.
-
The Swiss pharma’s dealmaking momentum continues in early 2024 with the acquisition of German biotech MorphoSys in an effort to strengthen its oncology portfolio.
-
MorphoSys Enters into Business Combination Agreement to be Acquired by Novartis for € 2.7 Billion Equity Value
2/5/2024
MorphoSys AG announced the company entered into a Business Combination Agreement with Novartis data42 AG and Novartis AG based on Novartis' intention to submit a voluntary public takeover offer for all outstanding MorphoSys no-par value bearer shares at an offer price of € 68.00 per share in cash.
-
MorphoSys Reports Preliminary 2023 Monjuvi U.S. Net Product Sales and Gross Margin, Provides 2024 Financial Guidance and Reduces Financial Liability
1/30/2024
MorphoSys AG reported preliminary Monjuvi ® U.S. net product sales and gross margin for Monjuvi U.S. net product sales for the full year of 2023 and provides its 2024 financial guidance.
-
MorphoSys to Present at the 42nd Annual J.P. Morgan Healthcare Conference
1/8/2024
MorphoSys AG announced that Jean-Paul Kress, M.D., Chief Executive Officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024, at 3:00 p.m. PST in San Francisco, California.
-
MorphoSys’ Pelabresib Improves All Four Hallmarks of Myelofibrosis in Phase 3 MANIFEST-2 Study
12/11/2023
MorphoSys AG announced comprehensive results from the Phase 3 MANIFEST-2 study investigating pelabresib, an investigational BET inhibitor, in combination with the JAK inhibitor ruxolitinib in JAK inhibitor-naïve patients with myelofibrosis.
-
The biopharma company remains committed to its investigational BET inhibitor pelabresib after it failed to meet one of two key endpoints.
-
Ad hoc: MorphoSys' Phase 3 Study of Pelabresib in Myelofibrosis Demonstrates Statistically Significant Improvement in Spleen Volume Reduction and Strong Positive Trend in Symptom Reduction
11/20/2023
MorphoSys AG announces strong topline results from the Phase 3 MANIFEST-2 study investigating pelabresib, an investigational BET inhibitor, in combination with the JAK inhibitor ruxolitinib compared with placebo plus ruxolitinib in JAK inhibitor-naïve patients with myelofibrosis.
-
Invitation to MorphoSys' Third Quarter and First Nine Months 2023 Financial Results Conference Call on November 16, 2023
11/9/2023
MorphoSys AG will publish its results for the third quarter and first nine months 2023 on November 15, 2023, at 10:00 pm CET.
-
MorphoSys To Showcase Phase 3 MANIFEST-2 Data on Pelabresib in Myelofibrosis in Oral Presentation at 2023 ASH Annual Meeting
11/2/2023
MorphoSys AG announced that data from the Phase 3 MANIFEST-2 trial of pelabresib, an investigational BET inhibitor, in combination with the JAK inhibitor ruxolitinib in JAK inhibitor-naïve patients with myelofibrosis will be presented during an oral presentation on Sunday, December 10, at the 65th American Society of Hematology Annual Meeting and Exposition.
-
MorphoSys Reports Preliminary Q3 2023 Monjuvi U.S. Sales and Gross Margin, and Updates Financial Guidance for 2023
10/25/2023
MorphoSys AG reported preliminary Monjuvi® U.S. Net Product Sales and Gross Margin for the third quarter of 2023 and provided an update to its financial guidance for 2023.
-
MorphoSys Receives U.S. FDA Fast Track Designation for Tulmimetostat in Endometrial Cancer
9/12/2023
MorphoSys AG (FSE:MOR)(NASDAQ:MOR) today announced that the U.S. Food and Drug Administration (FDA) granted Fast Track designation for tulmimetostat, the company's investigational next-generation dual inhibitor of EZH2 and EZH1, for the treatment of patients with advanced, recurrent or metastatic endometrial cancer harboring AT-rich interacting domain containing protein 1A (ARID1A) mutations and who have progressed on at least one prior line of treatment.
-
MorphoSys AG Reports Second Quarter and First Half 2023 Financial Results
8/9/2023
MorphoSys AG reports results for the second quarter and first half year of 2023.
-
MorphoSys AG Reports First Quarter 2023 Financial Results
5/3/2023
MorphoSys AG (FSE: MOR; NASDAQ: MOR) reports results for the first quarter of 2023.
-
Invitation to MorphoSys’ First Quarter 2023 Financial Results Conference Call on May 4, 2023
4/27/2023
MorphoSys AG will publish its results for the first quarter 2023 on May 3, 2023 at 10:00 pm CEST.
-
MorphoSys AG Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
3/15/2023
MorphoSys AG (FSE: MOR; NASDAQ: MOR) reports results for the fourth quarter and the full year 2022.
-
Invitation to MorphoSys' Full Year Results 2022 Conference Call on March 16, 2023
3/9/2023
MorphoSys AG (FSE:MOR)(NASDAQ:MOR) will publish its results for the financial year 2022 on March 15, 2023 at 09:00 pm CET (08:00 pm GMT; 04:00 pm EDT).
-
MorphoSys Stops Work and Operations on Pre-Clinical Research Programs
3/2/2023
MorphoSys AG announced that the company will stop work and operations on its pre-clinical research programs to optimize its cost structure.
-
Ad hoc: MorphoSys Stops Work and Operations on Pre-Clinical Research Programs and Reduces Workforce at its Germany Headquarters
3/2/2023
MorphoSys AG announces that it will stop work and operations on its pre-clinical research programs to optimize its cost structure.